JHJanet Hardy

Janet Hardy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Janet Hardy has a total of 187 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Liver enzyme effects of medicinal cannabis in advanced cancer: a substudy of two randomised trials

    by Luke Scarborough, Janet Hardy, Taylan Gurgenci, Georgie Huggett, Anita Pelecanos, Lachlan Webb, Ristan Greer, Phillip Good

    Objectives: This substudy investigated whether medicinal cannabis causes an elevation in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) in patients with advanced malignancy and determined whether different cannabis formulations (cannabidiol (CBD) alone vs tetrahydrocannabinol (THC)/CBD combination) had differing effects on enzyme levels. Methods: This analysis used data from two multicentre, randomised, placebo-controlled trials of escalating doses of CBD (MedCan1) or THC/CBD (MedCan2), including 287 patients with advanced cancer. Participants received escalating doses of CBD, THC/CBD or placebo. ALT and AST levels were measured at baseline, day 14 and day 28. Results: Medicinal cannabis did not cause elevation of ALT or AST in patients with advanced malignancy at the doses studied (up to 600 mg CBD/day). No clinically meaningful differences in liver enzyme levels were observed between CBD-only and CBD/THC combination products. Furthermore, no patients in the cannabis groups exceeded the predefined thresholds of 3× upper limit of normal (ULN) (or 5× ULN in those with liver metastases) for ALT or AST. Conclusions: In patients with advanced malignancy enrolled in two clinical trials, medicinal cannabis products did not have a significant adverse impact on ALT or AST levels during the first 4 weeks of use at the doses studied.

  • Genomic variation in symptom expression in castrate-resistant prostate cancer

    by Janet Hardy, Ristan Greer, Karyn Foster, Niara Oliveira, Phillip Good, Petra Vayne-Bossert, Adam D Ewing

    Objectives: Men with castrate-resistant prostate cancer (CRPC) suffer from symptoms related to both their disease and its treatment with marked variation between individuals with respect to symptom expression. This study aimed to determine whether genetic variation in cytokine expression is associated with symptom severity. Methods: An exploratory prospective, longitudinal consecutive patient cohort study was undertaken across two Queensland sites. Patient characteristics including tumour burden and current treatment were collected at baseline. Symptom severity was assessed 3–4 weekly for up to 6 assessments, with blood taken for genetic analysis once only during the study. Cytokine gene variants of each participant were assessed using a panel of single nucleotide polymorphisms (SNPs) most described in the literature. Results: Of the 66 participants, 27/66 (41%) had a low, and 39/66 (59%) a high tumour burden. Symptom severity was not related to tumour burden or patient characteristics. Of the 142 SNPs analysed from 62 participants, 15 SNPs from 7 genes were significantly associated with symptom severity. After Benjamini-Hochberg adjustment, SNPs rs2069772 from Interleukin-2 (IL2) and rs230494 from Nuclear Factor kappa-light-chain-enhancer of activated B cells (NFKb) remained significant. Conclusion: Although multiple factors can influence symptom severity, genetic variation may play a part. The early identification of men likely to develop severe symptoms during the course of their prostate cancer could theoretically enable symptoms to be managed more aggressively from an early stage. These preliminary findings need to be replicated in a larger cohort of men with CRPC.


  • Open Access

    Medicinal cannabis for symptom control in advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of 1:1 tetrahydrocannabinol and cannabidiol

    by Janet R. Hardy, Ristan M. Greer, Anita M. Pelecanos, Georgie E. Huggett, Alison M. Kearney, Taylan H. Gurgenci, Phillip D. Good

    Purpose: Patients with cancer commonly access cannabis hoping to relieve their symptoms. This study assessed whether a 1:1 10 mg/ml THC:CBD combination oil could improve total symptom burden in patients with advanced cancer over that provided by palliative care alone. Methods: Participants were randomised to medicinal cannabis (MC) or placebo oil; dose escalated over 14 days according to tolerance and efficacy and continued to day 28. Symptoms assessed using the Edmonton Symptom Assessment Scale (ESAS) were summated to give a total symptom distress score (TSDS). The primary outcome measure was the change from baseline in TSDS at day 14. Secondary outcomes included individual symptom scores, opioid use, participant-selected dose, QoL, psychological symptoms, global impression of change (GIC), and adverse effects. Results: The pre-planned sample size of 120 at day 14 was reached following the randomisation of 144 patients. Mean (SD) TSDS improved over time in both arms (− 6.30 (12.3) MC, − 6.98 (12.56) placebo, p = 0.76) to day 14 with no difference between arms. A statistically significant improvement in ESAS pain scores in the MC arm (mean (SD) − 1.42 (2.15) MC and − 0.46 (2.83) placebo, p = 0.04) was at the expense of greater psychomimetic toxicity. Improvement in general well-being was greater for the placebo. GIC and the pain component of QoL both favoured MC. Conclusions: Patients can be informed that a 1:1 THC:CBD combination cannabis oil was no better than palliative care alone in palliating symptoms in patients with advanced cancer. A small benefit in pain control was associated with greater toxicity. Trial registration: Australian New Zealand Clinical Trial Registry (ANZCTR): ACTRN12619000037101, 14/01/2019.


  • Has medicinal cannabis found a role in oncology/palliative care?

    by Janet R. Hardy, Phillip Good

  • Open Access

    Is there a role for hypnosis in palliative care?

    by Petra Vayne-Bossert, Janet Hardy

    Hypnosis has gained popular interest over the last few decades and has become increasingly subject to research study. Evidence of benefit in the palliative care setting is largely lacking, but it has been shown to have a favourable impact on psychological symptoms, especially anxiety, as well as chronic pain conditions. As a personalised approach, hypnotherapy is an excellent example of individual-centred care. Moreover, in the absence of significant adverse effects, it offers great promise as a complementary therapy.


  • Orally dissolving pilocarpine tablets for xerostomia in advanced cancer: A pilot N-of-1 feasibility study

    by Karyn Foster, Geoff Mitchell, Evan Richard, Kathryn J Steadman, Hugh Senior, Rose Estafanos, Janet Hardy

    Background: Xerostomia is a common and difficult symptom experienced by patients with cancer. Pilocarpine is a cholinergic agent that stimulates salivation. Aim: To assess the feasibility of conducting a N-of-1 trial to determine the efficacy of pilocarpine orally dissolving tablets in patients with xerostomia. Design: Double-blind, crossover, placebo-controlled N-of-1 trials of 5 mg pilocarpine tablets vs placebo. Each trial consisted of three 6-day cycles containing pilocarpine (3 days) and placebo (3 days) in random order. Setting/participants: Participants with advanced cancer and xerostomia (scoring >3 on an 11-point numerical rating scale) from any cause, were recruited from an inpatient and outpatient palliative care unit in Brisbane, Australia. Results: Eighteen people were recruited in 17 months. Nine withdrew, seven before or during the first 4 days. Three withdrew due to unacceptable side effects. Two participants met the definition of response (⩾2 point reduction in mean scores active vs placebo cycles). When assessing individual cycles, 15 out of 27 cycles (56%) met the definition of response. More people reported at least one mild episode during pilocarpine than placebo of nausea (6 vs 3), vomiting (3 vs 0) and sweating (3 vs 2). About 48% of adverse event classifications were reported in placebo cycles only. Conclusion: Recruitment to an N-of-1 trial for xerostomia is feasible but attrition was high (50%). Early dropout may have been due to the trial length, complexity, appropriateness or number of questionnaires. Adverse events were generally mild. Two of 10 participants were considered to have benefited from pilocarpine warranting ongoing treatment.


  • Open Access

    Exploring potential anti-inflammatory effects of medicinal cannabis

    by Taylan Gurgenci, Gregor Kijanka, Ristan Greer, Georgie Huggett, Phillip Good, Moniruzzaman, Janet Hardy

    Purpose: Inflammation is thought to play a key role in malignant disease and may play a significant part in the expression of cancer-related symptoms. Cannabidiol (CBD) is a bioactive compound in cannabis and is reported to have significant anti-inflammatory properties. Method: Serial C-reactive protein (CRP) levels were measured in all participants recruited to a randomised controlled trial of CBD versus placebo in patients with symptoms related to advanced cancer. A panel of inflammatory cytokines was measured over time in a subset of these patients. Results: There was no difference between the two arms in the trajectory of CRP or cytokine levels from baseline to day 28. Conclusion: We were unable to demonstrate an anti-inflammatory effect of CBD in cancer patients. Trial registration: ANZCTR 26180001220257, registered 20/07/2018.


  • Top Cited Papers

    Phase IIb Randomized, Placebo-Controlled, Dose-Escalating, Double-Blind Study of Cannabidiol Oil for the Relief of Symptoms in Advanced Cancer (MedCan1-CBD)

    by Janet Hardy, Ristan Greer, Georgie Huggett, Alison Kearney, Taylan Gurgenci, Phillip Good

    PURPOSE: To determine whether cannabidiol (CBD) oil can improve symptom distress in patients with advanced cancer receiving palliative care. METHODS: Participants were adults with advanced cancer and symptom distress (Edmonton Symptom Assessment Scale [ESAS] total score of ≥ 10/90) who received titrated CBD oil 100 mg/mL, 0.5 mL once daily to 2 mL three times a day, or matched placebo for 28 days. The primary outcome was ESAS total symptom distress score (TSDS) at day 14. Response was defined as a decrease in TSDS by ≥ 6 at day 14. Secondary outcomes were ESAS TSDS over time, individual symptom scores, patient-determined effective dose, opioid use, Global Impression of Change, depression, anxiety, quality of life, and adverse events. RESULTS: Of the 144 patients randomly assigned, the planned sample size of 58 participants on CBD and 63 on placebo reached the primary analysis point (day 14). The unadjusted change in TSDS from baseline to day 14 was –6.2 (standard deviation, 14.5) for placebo and –3.0 (standard deviation, 15.2) for CBD with no significant difference between arms ( P = .24). Similarly, there was no detected difference in proportion of responders (placebo: 37 of 63 [58.7%], CBD: 26 of 58 [44.8%], P = .13). All components of ESAS improved (fell) over time with no difference between arms. The median dose of participant-selected CBD was 400 mg per day with no correlation with opioid dose. There was no detectable effect of CBD on quality of life, depression, or anxiety. Adverse events did not differ significantly between arms apart from dyspnea that was more common with CBD. Most participants reported feeling better or much better at days 14 (53% CBD and 65% placebo) and 28 (70% CBD and 64% placebo). CONCLUSION: CBD oil did not add value to the reduction in symptom distress provided by specialist palliative care alone.


  • Open Access

    Results from a type two hybrid‐effectiveness study to implement a preoperative anemia and iron deficiency screening, evaluation, and management pathway

    by Alana Delaforce, Shannon Farmer, Jed Duff, Judy Munday, Kristin Miller, Lynne Glover, Chris Corney, Gareth Ansell, Naadir Gutta, Haitham Tuffaha, et al.

    Background: Implementation of pathways to screen surgical patients for preoperative anemia and iron deficiency remains limited. This study sought to measure the impact of a theoretically informed, bespoke change package on improving the uptake of a Preoperative Anemia and Iron Deficiency Screening, Evaluation, and Management Pathway.Study Design and Methods: Pre‐post interventional study using a type two hybrid‐effectiveness design evaluated implementation. Four hundred (400) patient medical record reviews provided the dataset (200 pre‐ and 200‐post implementation). The primary outcome measure was compliance with the pathway. Secondary outcome measures (clinical outcomes) were anemia on day of surgery, exposure to a red blood cell (RBC) transfusion, and hospital length of stay. Validated surveys facilitated data collection of implementation measures. Propensity score‐adjusted analyses determined the effect of the intervention on clinical outcomes, and a cost analysis determined the economic impact.Results: For the primary outcome, compliance improved significantly post‐implementation (Odds Ratio 10.6 [95% CI 4.4–25.5] p < .000). In secondary outcomes, adjusted analyses point estimates showed clinical outcomes were slightly improved for anemia on day of surgery (Odds Ratio 0.792 [95% CI 0.5–1.3] p = .32), RBC transfusion (Odds Ratio 0.86 [95% CI 0.41–1.78] p = .69) and hospital length of stay (Hazard Ratio 0.96 [95% CI 0.77–1.18] p = .67), although these were not statistically significant. Cost savings of $13,340 per patient were realized. Implementation outcomes were favorable for acceptability, appropriateness, and feasibility.Conclusion: The change package significantly improved compliance. The absence of a statistically significant change in clinical outcomes may be because the study was powered to detect an improvement in compliance only. Further prospective studies with larger samples are needed. Cost savings of $13,340 per patient were achieved and the change package was viewed favorably.